Acute Application of Pegvisomant and Octreotide in Acromegaly

The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment

The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.

Inclusion Criteria:

• patients with acromegaly currently on stable pegvisomant therapy
• patients with diabetes mellitus may be included. Glucose levels must be controlled regularly throughout the study
• patients must not be co-treated with any other medication for acromegaly

Exclusion Criteria:

• radiotherapy within the last 2 years
• any relevant acute disease
• history of hypersensitivity against any of the used drugs
• pregnancy or lactation
• abnormal baseline findings